Comparative Pharmacology
Head-to-head clinical analysis: LUFYLLIN versus SLO PHYLLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUFYLLIN versus SLO PHYLLIN.
LUFYLLIN vs SLO-PHYLLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular cAMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/mL injection, administer 200-400 mg IM or slow IV every 6-8 hours.
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator